Clinical Trial

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Study acronym: (KISV)
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-02-07; most recent amendment 2026-02-19.
Status change: Not Yet Recruiting → Recruiting 2023-02-28
Trial Details
NCT Number NCT05732272
Lead Sponsor University of Kansas Medical Center
Conditions Smoking Cessation
Enrollment 500 participants
Start Date 2023-02-28
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-23